Trial Profile
SLF CIL36590 Phase IIb COPD
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2016
Price :
$35
*
At a glance
- Drugs SLFCIL 36590 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 21 Jul 2016 New trial record